GlassScriptPhysician profile
Blake Ellington Moore
NPI 1326215518
$100,018.80
in general payments reported to CMS, 2019-2025
26 companies · $39K in 2025
The $39K reported for 2025 was more than what 94% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,706 · 2020: $8,793 · 2021: $4,307 · 2022: $17K · 2023: $11K · 2024: $17K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $8,667 · Food and Beverage: $3,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,990.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,000.00 |
| Travel and Lodging | $8,666.76 |
| Food and Beverage | $3,747.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $22,464.61 | 2019-2025 | Motoband, Minibunion, N/A |
| Medical Device Business Services, INC. | $21,416.62 | 2023-2025 | Motoband, Tfn-Advance |
| Arthrex, INC. | $16,276.36 | 2019-2025 | Distal Extremities Implants Foot & Ankle Ttc Nail, Distal Extremities Implants Soft Tissue Ib Ligament Augmentation |
| Curvebeam LLC | $7,000.00 | 2020-2023 | |
| Synthes USA Products LLC | $6,696.00 | 2024 | |
| Fortis Surgical, LLC | $5,903.21 | 2019-2025 | |
| Restor3d, INC. | $4,799.96 | 2022-2024 | |
| Depuy Synthes Products, INC. | $4,722.00 | 2025 | |
| Crossroads Extremity Systems, LLC | $3,032.90 | 2019-2021 | |
| Flower Orthopedics Coporation | $2,823.09 | 2025 | |
| Treace Medical Concepts, INC. | $1,453.94 | 2023-2024 | |
| Supreme Orthopedic Systems, LLC | $1,169.00 | 2019 | |
| Medline Industries LP | $761.32 | 2022-2025 | |
| Exactech, INC. | $541.04 | 2019 | |
| Stryker Corporation | $271.16 | 2024-2025 | Augment Injectable, Infinity Adaptis, Prostep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $141.74 | 2019 | |
| Trimed, INC. | $114.55 | 2025 | |
| Bioventus LLC | $111.18 | 2024 | Exogen Ultrasound Bone Healing System |
| Forma Medical | $109.68 | 2025 | Optimal Ht |
| Astellas Pharma US INC | $78.73 | 2019-2022 | |
| Kuros Biosciences USA, INC | $61.35 | 2025 | Magnetos |
| Paragon 28, INC. | $23.64 | 2020 | |
| Rochester Medical Corporation | $17.13 | 2022 | |
| Dynasplint Systems INC. | $14.91 | 2025 | Dynasplint |
| Pfizer INC. | $14.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.